GHD Clinical Trial
Official title:
The Efficacy and Safety of Once-weekly PEG-somatropin (GenSci004) in Treatment-naive Children With Growth Hormone Deficiency: A Randomized, Open-label, Parallel-group, Active-Controlled, Non-inferiority Phase 3 Study (ELEVATE)
The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.
The purpose of this Phase 3 study is to evaluate the efficacy, safety, and tolerability of weekly GenSci004 compared to daily Genotropin over 52 weeks in prepubertal treatment-naïve children with growth failure due to GHD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00553852 -
Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity
|
Phase 3 | |
| Not yet recruiting |
NCT06024967 -
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
|
Phase 3 |